PARP Inhibitor Combination Therapy Boosts Antitumor Activity in NSCLC Models

Pairing HER3-DXd with the PARP inhibitor olaparib increased DNA damage, induced apoptosis, and slowed tumor progression in vivo in preclinical non-small cell lung cancer models.